142 related articles for article (PubMed ID: 27014847)
1. Systematic comparison of the mono-, dimethyl- and trimethyl 3-hydroxy-4(1H)-pyridones - Attempted optimization of the orally active iron chelator, deferiprone.
Xie YY; Lu Z; Kong XL; Zhou T; Bansal S; Hider R
Eur J Med Chem; 2016 Jun; 115():132-40. PubMed ID: 27014847
[TBL] [Abstract][Full Text] [Related]
2. CN128: A New Orally Active Hydroxypyridinone Iron Chelator.
Chen W; Yuan X; Li Z; Lu Z; Kong S; Jiang H; Du H; Pan X; Nandi M; Kong X; Brown K; Liu Z; Zhang G; Hider RC; Yu Y
J Med Chem; 2020 Apr; 63(8):4215-4226. PubMed ID: 32208614
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of a novel oral iron chelator: 1-(N-Acetyl-6-Aminohexyl)-3-Hydroxy-2-Methylpyridin-4-one.
Pangjit K; Banjerdpongchai R; Phisalaphong C; Fucharoen S; Xie YY; Lu ZD; Hider RC; Srichairatanakool S
J Pharm Pharmacol; 2015 May; 67(5):703-13. PubMed ID: 25627251
[TBL] [Abstract][Full Text] [Related]
4. Incorporation by coordination and release of the iron chelator drug deferiprone from zinc-based metal-organic frameworks.
Burrows AD; Jurcic M; Keenan LL; Lane RA; Mahon MF; Warren MR; Nowell H; Paradowski M; Spencer J
Chem Commun (Camb); 2013 Dec; 49(96):11260-2. PubMed ID: 24135827
[TBL] [Abstract][Full Text] [Related]
5. Fast biological iron chelators: kinetics of iron removal from human diferric transferrin by multidentate hydroxypyridonates.
Turcot I; Stintzi A; Xu J; Raymond KN
J Biol Inorg Chem; 2000 Oct; 5(5):634-41. PubMed ID: 11085654
[TBL] [Abstract][Full Text] [Related]
6. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
Rombos Y; Tzanetea R; Konstantopoulos K; Simitzis S; Zervas C; Kyriaki P; Kavouklis M; Aessopos A; Sakellaropoulos N; Karagiorga M; Kalotychou V; Loukopoulos D
Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
Rai BL; Dekhordi LS; Khodr H; Jin Y; Liu Z; Hider RC
J Med Chem; 1998 Aug; 41(18):3347-59. PubMed ID: 9719587
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel pegylated iron chelators with decreased metabolic rate.
Li J; Lu Z; Kong X; Ma Y; Zhang X; Bansal SS; Abbate V; Hider RC
Future Med Chem; 2015; 7(18):2439-49. PubMed ID: 26670054
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans.
Thuma PE; Olivieri NF; Mabeza GF; Biemba G; Parry D; Zulu S; Fassos FF; McClelland RA; Koren G; Brittenham GM; Gordeuk VR
Am J Trop Med Hyg; 1998 Mar; 58(3):358-64. PubMed ID: 9546419
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
Dobbin PS; Hider RC; Hall AD; Taylor PD; Sarpong P; Porter JB; Xiao G; van der Helm D
J Med Chem; 1993 Aug; 36(17):2448-58. PubMed ID: 8355246
[TBL] [Abstract][Full Text] [Related]
11. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.
Kontoghiorghes GJ; Aldouri MA; Sheppard L; Hoffbrand AV
Lancet; 1987 Jun; 1(8545):1294-5. PubMed ID: 2884415
[TBL] [Abstract][Full Text] [Related]
12. Design of orally active iron chelators.
Hider RC; Choudhury R; Rai BL; Dehkordi LS; Singh S
Acta Haematol; 1996; 95(1):6-12. PubMed ID: 8604587
[TBL] [Abstract][Full Text] [Related]
13. Hydroxypyridinones with enhanced iron chelating properties. Synthesis, characterization and in vivo tests of 5-hydroxy-2-(hydroxymethyl)pyridine-4(1H)-one.
Lachowicz JI; Nurchi VM; Crisponi G; Jaraquemada-Pelaez MG; Arca M; Pintus A; Santos MA; Quintanova C; Gano L; Szewczuk Z; Zoroddu MA; Peana M; Domínguez-Martín A; Choquesillo-Lazarte D
Dalton Trans; 2016 Apr; 45(15):6517-28. PubMed ID: 26956442
[TBL] [Abstract][Full Text] [Related]
14. Effect of oral iron chelator L1 on iron absorption in man.
Dresow B; Fischer R; Nielsen P; Gabbe EE; Piga A
Ann N Y Acad Sci; 1998 Jun; 850():466-8. PubMed ID: 9668586
[No Abstract] [Full Text] [Related]
15. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
[TBL] [Abstract][Full Text] [Related]
16. Anti-leukemia activity of 7-hydroxy-2-substituted-methyl-5H-oxazolo[3,2-a]pyrimidin-5-one derivatives.
Guillon J; Mamani-Matsuda M; Massip S; Leger JM; Thiolat D; Mossalayi D; Jarry C
J Enzyme Inhib Med Chem; 2002 Dec; 17(6):391-6. PubMed ID: 12683674
[TBL] [Abstract][Full Text] [Related]
17. Iron(III) chelating resins II. 3-Hydroxy-4(1H)-pyridinones-sepharose gels.
Feng M; van der Does L; Bantjes A
J Biomater Sci Polym Ed; 1992; 4(2):145-54. PubMed ID: 1486065
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials with oral iron chelator L1.
Kontoghiorghes GJ; Hoffbrand AV
Lancet; 1989 Dec 23-30; 2(8678-8679):1516-7. PubMed ID: 2574781
[No Abstract] [Full Text] [Related]
19. Design, synthesis and evaluation of N-basic substituted 3-hydroxypyridin-4-ones: orally active iron chelators with lysosomotrophic potential.
Liu ZD; Khodr HH; Lu SL; Hider RC
J Pharm Pharmacol; 2000 Mar; 52(3):263-72. PubMed ID: 10757413
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic disposition of the oral iron chelator deferiprone in the domestic pigeon (Columba livia).
Whiteside DP; Barker IK; Conlon PD; Tesoro A; Thiessen JJ; Mehren KG; Jacobs RM; Spino M
J Avian Med Surg; 2007 Jun; 21(2):121-9. PubMed ID: 18065133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
